Recent real-world analyses are mixed: a U.S. cohort study of > 25 000 initiators reported comparable risks for myocardial infarction, stroke and mortality but a lower hazard for heart-failure events with first-line SGLT2 inhibition versus metformin [5,6]. The gene discussed is SLC5A2; the disease is heart failure.